Q-omics provides the consensus-scored CD72 profile across patient tissues and cancer cell-line models. CD72 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CD72 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CD72 RNA expression shows 21,090 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CD72 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD72 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD72 survival associations across molecular data types. CD72 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD72 RNA expression–survival associations across cancer types. High CD72 expression shows unfavorable associations in KIRC, KIRP, LGG, ACC and LUSC, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CD72 RNA expression.
This table summarizes CD72 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CD72. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD72 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, STAD, KIRP and BRCA. The KIRC box plot shows higher CD72 RNA expression in tumor versus normal tissue (log2 FC = +2.112, t-test p < 0.001).
This table shows molecular features associated with CD72 in patient tissues and cancer cell lines. In patient samples, CD72 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD72 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
